Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?

Social Science and Medicine

Volumn 131, Issue , 2015, Pages 207-214

  Davis, Courtney ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical benefit; End of life cancer care; Expectations; Overtreatment; Patient preferences; Pharmaceuticalization; United Kingdom; United States

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL PRACTICE; DRUG MISUSE; FORECASTING; HUMAN; INFORMED CONSENT; NEOPLASMS; PATIENT ADVOCACY; PATIENT PREFERENCE; TERMINAL CARE; TREATMENT OUTCOME; TRENDS; UNITED KINGDOM; UNITED STATES; UNNECESSARY PROCEDURE;

ANTINEOPLASTIC AGENTS; FORECASTING; GREAT BRITAIN; HUMANS; INFORMED CONSENT; NEOPLASMS; PATIENT ADVOCACY; PATIENT PREFERENCE; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUG OVERUSE; TERMINAL CARE; TREATMENT OUTCOME; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 84925444094     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.12.007     Document Type: Article

References (121)

1. Abraham J. Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008. J. Health Polit. Policy Law 2009, 34(6):931-977.
2. Abraham J. Pharmaceuticalisation of society in context: theoretical, empirical and health dimensions. Sociology 2010, 4(4):603-622.
3. Altwairgi A.K., Booth C.M., Hopman W.M., Baetz T.D. Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer. J. Clin. Oncol. 2012, 30(28):3552-3557.
4. Amir E., Seruga B., Kwong R., Tannock I.F., Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?. Eur. J. Cancer 2012, 48:385-388.
5. Analysis Group Innovation in the Biopharmaceutical Pipeline: a Multidimensional View, January 2013 2013, Available at:, (accessed 14.11.13.). http://phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf.
6. Anon Overoptimism about cancer. Lancet 2000, 355(9199):157.
7. Anon Wellcome Trust Monitor 1: Key Points, the Wellcome Trust, March 2010 2010, Available at:, (accessed 14.11.13.). http://www.wellcome.ac.uk/stellent/groups/corporatesite/@msh_grants/documents/web_document/wtx058869.pdf.
8. Bach P.B., Saltz L.B., Wittes R.E. In Cancer Care, Cost Matters, the New York Times, 14 October 2012 2012, Available at:, (accessed 22.05.14.). http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html?_r=0.
9. Berger M.L., Eck S., Ruberg S.J. Raising the bar of efficacy for drug approval requires an understanding of patient diversity. J. Clin. Oncol. 2010, 28:e343-e344. Author reply e5.
10. Bernards N., Creemers G.J., Nieuwenhuijzen G.A.P., et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann. Oncol. 2013, 24(12):3056-3060.
11. Booth C. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. Clin. Cancer Res. 2010, 16:5963-5971.
12. Booth C.M., Dranitsaris G., Gainford M.C., Berry S., Fralick M., Fralick J., Sue J., Clemons M. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast Cancer. BMC Cancer 2007, 7:110. 10.1186/1471-2407-7-110.
13. Booth C.M., Eisenhauer E.A. Progression-free survival: meaningful or simply measurable?. J. Clin. Oncol. 2012, 30(10):1030-1033.
14. Braga S., Miranda A., Fonsensca R., et al. The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychoonology 2007, 16:863-868.
15. Braga S. Why do our patient get chemotherapy until the end of life?. Ann. Oncol. 2011, 22:2345-2348.
16. Busfield J. 'A pill for every ill': explaining the expansion in medical use. Soc. Sci. & Med. 2010, 70:934-941.
17. Colombet I., Motheil V., Durand J.-P., et al. Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients. BMJ Support. Palliat. Care 2012, 2:239-247.
18. Colon Cancer Alliance (undated) Two New Drugs Bring Hope for Stage IV Patients. Available at:. Accessed 5 September 2014. http://www.ccalliance.org/crc_news/articles/two_new_drugs.html.
19. Corner J., Wright D., Hopkinson J., et al. The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study. Br. J. Cancer 2007, 96:875-881.
20. Davis C., Abraham J. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociol. Health Illn. 2011, 33(5):731-747.
21. Davis C., Abraham J. Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science 2013, Palgrave, London.
22. Donovan K.A., Greene P.G., Shuster J.L., Partridge E.E., Tucker D.C. Treatment preferences in recurrent ovarian cancer. Gynecol. Oncol. 2002, 86:200-211.
23. Doyle C., Crump M., Pintilie M., Oza A.M. Does palliative chemotherapy palliate? evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 2001, 19(5):1266-1274.
24. Earle C.C. It take a village. J. Clin. Oncol. 2011, 30(4):353-354.
25. Earle C.C., Neville B.A., Landrum M.B., et al. Trends in the aggressiveness of cancer care near the end of life. J. Clin. Oncol. 2004, 22(2):315-321.
26. Earle C.C., Landrum M.B., Souza J.M., et al. Aggressiveness of cancer care near the end of Life: is it a quality-of-care issue?. J. Clin. Oncol. 2008, 26(2300):3860-3866.
27. Ellis L.M., Bernstein D.S., Voest E.E., Berlin J.D., Sargent D., et al. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 17 March 2014, 10.1200/JCO.2013.53.8009.
28. Emanuel E.J., Young-Xu Y., Levinsky N.G., et al. Chemotherapy use among medicare beneficiaries at the end of life. Ann. Intern. Med. 2003, 138(8):639-643.
29. EU Patient Advocate A Interview with EU Cancer Patient Advocate 2012, 13 August 2012.
30. European Commission Analysis of the Effects of a Joint Technology Initiative in the Area of INNOVATIVE MEDICINES 2007, 15.5.2007, Commission of the European Communities, Brussels.
31. Express Scripts Drug Trend Report. October 2013 2013, Available:, (accessed 05.09.14.). http://lab.express-scripts.com/%7E/media/previous%20reports%20pdfs/drug%20trend%20report%202012.ashx.
32. Express Scripts Drug Trend Report. April 2014 2014, Available:, (accessed 05.09.14.). http://lab.express-scripts.com/%7E/media/pdfs/drug%20trend%20report/express%20scripts%202013%20drug%20trend%20report.ashx.
33. Fallowfield L.J., Fleissig A. The value of progression-free survival to patients with advanced-stage cancer. Nat. Rev. Clin. Oncol. 2012, 9:41-47.
34. Fallowfield L.J., Jenkins V. Psychosocial issues in breast cancer. Companion to Specialist Practice Volume in Breast Surgery Fourth Edition Elsevier, Chapter 16 2013, 245-257.
35. FDA Innovation or Stagnation: Challenge and Opportunity on the Critical Path to new Medical Products March 2004, Food and Drug Administration, Available at:, (accessed 22.05.14.). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPAthOpportunitiesReports/ucm113411.pdf.
36. FDA FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans 5 October 2011, FDA News Release, Available at:, (accessed 22.05.14.). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274538.htm.
37. Fishman J., Ten Have T., Casarett D. Cancer and the media. How does the news report on treatment and outcomes?. Arch. Intern. Med. 2010, 170(6):515-518.
38. Fojo T., Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 2009, 101:1044-1048.
39. Fojo T., Parkinon D.R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are We achieving too little by giving too Much?. Clin. Cancer Res. 2010, 16:5972-5980.
40. Fojo T., Mailankody S., Lo A. Unintended consequences of expensive cancer therapeutics: the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity. JAMA Otolaryngol. 2014, Published online July 28 2014. 10.1001/jamaoto.2014.1570.
41. Gabe J., Chamberlain K., Norris P., Dew K., Madden H., Hodgetts D. The debate about the funding of herceptin: a case study of 'countervailing powers'. Soc. Sci. & Med. 2012, 75:2353-2361.
42. Gale E.A.M. Lessons from the glitazones. Lancet 2001, 357:1870-1875.
43. Garattini S., Bertele V. Efficacy, safety and cost of new anticancer drugs. BMJ 2002, 325:269-271.
44. Goss T.F., Picard E.H., Tarab A. Recognizing Value in Oncology Innovation, White Paper June 2012, Boston Healthcare, Washington DC.
45. Greer J.A., Pirl W.F., Jackson V.A., Muzikansky A., et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol. 2011, 30(4):394-400.
46. Gutman S.I., Piper M., Grant M.D., et al. Progression-free Survival: What Does it Mean for Psychological Well-being or Quality of Life? 2013, Methods Research Report. April 2013. AHRQ Publication No. 13-EHC074-EF, AHRQ., Rockville, MD, Available at:, (accessed 14.11.13.). http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
47. Hall S.S. The Cost of Living 2013, New York Magazine, October 20. Available at:, (accessed 14.11.13.). http://nymag.com/news/features/cancer-drugs-2013-10/.
48. Harper M. The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough 23 June 2013, Forbes, Available at:, (accessed 14.11.13.). http://www.forbes.com/sites/matthewherper/2013/06/23/the-fdas-cancer-czar-says-he-cant-approve-new-drugs-fast-enough/.
49. Harrington S.E., Smith T.J. The role of chemotherapy at the end of life: when is enough, enough?. JAMA 2008, 299(22):2667-2678.
50. Hill K.P., Ross J.S., Egilman D.S., Krumholz H.M. The ADVANTAGE seeding trial: a review of internal documents. Ann. Intern. Med. 2008, 149(4):251-258.
51. Hind D., Wailoo A.J., Sutcliffe P. Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles. Health Expect. 2011, 14:38-47.
52. Ho T.H., Barbera L., Saskin R., et al. Trends in the aggressiveness of end-of-life Cancer care in the universal health care system of Ontario, Canada. J. Clin. Oncol. 2011, 29(12):1587-1591.
53. Hope J. New Drug for Advanced Bowel cancer can Increase Patients' Lives by Six Weeks 2013, Mail Online, 4 March 2013. Available at:, (accessed 14.11.13.). http://www.dailymail.co.uk/health/article-2287613/New-drug-advanced-bowel-cancer-increase-patients-lives-weeks.html.
54. INCa Situation de la chimiotherapie des cancers en 2011, Collection Rapports & synthese, ouvrage collectif edite par l'INCa, Institut National de Cancer June 2012, INCa, Paris.
55. Johnson D.H. Setting the bar for therapeutic trials in non-small-cell lung Cancer: how low can we go?. J. Clin. Oncol. 2014, 32(14):1389-1391.
56. Jonsson B., Wilking N. Aglobal comparison regarding patient access to cancer drugs. Ann. Oncol. 2007, 18(Suppl.3).
57. Kanavos P., Sullivan R., Lewison G., Schurer W., Eckhouse S., Viachopioti Z. The role of funding and policies on innovation in cancer drug development. eCancer 2010, 4:164. 10.3332/ecancer.2010.164.
58. Kantarjian H.M., Fojo T., Mathsien M., Zwelling L.A. Cancer drugs in the United States: Justum Pretium - the just price. J. Clin. Oncol. 2013, Published online May 6, 2013. 10.1200/JCO.2013.49.1845.
59. Keating N.L., Landrum M.B., Lamont E.B., et al. End-of-life care for Older Cancer patients in the veterans health adminsitration versus the private sector. Cancer August 2010, 1:3732-3739.
60. Koedoot C.G., de Haan R.J., Stiggelbour A.M., et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. Br. J. Cancer 2003, 89:2219-2226.
61. Lewison G., Tootell S., Roe P., Sullivan R. How do the media report cancer research? A study of the UK's BBC website. Br. J. Cancer 2008, 99:569-576.
62. Light D.W. Bearing the risks of Prescription drugs. The Risks of Prescription Drugs 2010, Columbia University Press, New York. D.W. Light (Ed.).
63. Mack J.W., Weeks J.C., Wright A.A., Block S.D., Prigerson H.G. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J. Clin. Oncol. 2010, 28(7):1203-1208.
64. Mack J.W., Smith T.J. Reasons why physicians do not have discussions about poor prognosis, why its matters, and what can Be improved. J. Clin. Oncol. 2012, 30(22):2715-2717.
65. Martoni A.A., Taneberger S., Mutri V. Cancer chemotherapy near the end of life: the Time has come to set guidelines for its appropriate use. Tumori 2007, 93:417-422.
66. Matsuyama R., Reddy S., Smith T.J. Why do patients choose chemotherapy near the end of life? a review of the perspective of those facing death from cancer. J. Clin. Oncol. 2006, 24(21):3490-3496.
67. Mayer M. From access to evidence: an Advocate's journey. J. Clin. Oncol. 2003, 21(2):3881-3884.
68. Mayer M. Letter to Richard Pazdur, 30th August, 2010 2010, (unpublished).
69. Mello M.M., Brennan T.A. The controvery over high-Dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff. 2001, 20(5):101-117.
70. Mende M., Trautmann K., Rentsch, et al. Patients' perspective on palliative chemotherapy of colorectal and non-colorectal cancer: a prospective study in chemotherapy-exposed population. BMC Cancer 2013, 13:66.
71. Morita T., Akechi T., Ikenaga M., et al. Communication about the ending of anticancer treatment and transition to palliative care. Ann. Oncol. 2004, 15:1551-1557.
72. Mukherjee S. The Emperor of all Maladies: A Biography of Cancer 2011, HarperCollins, London.
73. Murillo J.R., Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncol. 2006, 11:1095-1099.
74. Nappa U., Lindqvist O., Rasmussen B.H., Axelsson B. Palliative chemotherapy during the last month of life. Ann. Oncol. 2011, 11:2375-2380.
75. NCCN Palliative Care Version 2.2013 2013, National Comprehensive Cancer Network Guidelines.
76. Niraula S., Seruga B., Ocana A., et al. The price we pay for progress: a meta-analysis of the harms of newly approved anticancer drugs. J. Clin. Oncol. 2012, 20(24):3012-3019.
77. O'Brien M.E.R., Borthwick A., Rigg A., Leary A., Assersohn L., Last K., Tan S., Milan S., Tait D., Smith E.E. Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br. J. Cancer 2006, 95:1632-1636.
78. Ocana A., Tannock I.F. When are 'Positive' clinical trials in oncology Truly positive?. J. Natl. Cancer Inst. 2011, 103(1):16-20.
79. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008, 13(Suppl.2):19-21.
80. Rasmussen N., Lee K., Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials 2009, 10:116. 10.1186/1745-6215-10-116.
81. Renouf D.J., Lim H.J., Speers C., et al. Survival for metastatic colorectal cancer in the Bevacizumab ear: a population-based analysis. Clin. Colorectal Cancer 2011, 10(2):97-101.
82. Roche M.F., Ridha J., Edwards S., Lloyd K., Forsey S. Chemotherapy Trends for Patients with Solid Tumours in One English Cancer Network 2010, Oxford Cancer Intelligence Unit, Available at:, (accessed 14.11.13.). http://www.ociu.nhs.uk/cancer-intelligence/information-service-1/ChemotherapytrendsforpatientswithsolidtumoursinoneEnglishcancernetwork.pdf.
83. Rocque G.B., Cleary J.F. Palliative care reduces morbidity and mortality in cancer. Nat. Rev. Clin. Oncol. 2013, 10:80-89.
84. Sacher A.G., Le L.W., Leighl N.B. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. J. Clin. Oncol. 2014, 32(14):1407-1411.
85. Saito A.M., Landrum M.B., Neville B.A., Ayanian J.Z., Earle C.C. The effect on survival of continuing chemotherapy to near death. BMC Palliat. Care 2011, 10:14.
86. Salz L. Progress in cancer care: the hope, the hype, and the gap between reality and perception. J. Clin. Oncol. 2009, 26(31):5020-5021.
87. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 2010, 9:363366.
88. Schnipper L.E., Smith T.J., Raghavan D., Blayney D.W., Ganz P.A., Mulvey T.M., et al. American Society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J. Clin. Oncol. 2012, 30:1715-1724.
89. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N. Engl. J. Med. 2004, 351(4):317-319.
90. Seruga B., Hertz P.C., Wang L., et al. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann. Oncol. 2010, 21:1411-1418.
91. Shah B.K., Ghimire K.B. Survival trends among patients with advanced renal cell carcinoma (RCC) in the United States. J. Clin. Oncol. 2013, 31(Suppl.6). Abstract 422.
92. Sherman R.E., Li J., Shapley S., Robb M., Woodcock J. Exediting drug development - the FDA's new "Breakthrough Therapy" designation. N. Engl. J. Med. 2013, 369(20):1877-1880.
93. Silverstri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br. Med. J. 1998, 317:771-775.
94. Sobrero A., Bruzzi P. Incremental advance or seismic shift? the need to raise the bar of efficacy for drug approval. J. Clin. Oncol. 2009, 27(35):5868-5873.
95. Sullivan R., Peppercorn J., Sikora K., Zalcberg J., Merepol N.J., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011, 12:930-980.
96. Swetz K.M., Smith T.J. Palliative chemotherapy. When is it Worth it and when is it not?. Cancer J. 2010, 16(5):467-472.
97. Temel J.S., McCannon J., Greer J.A., et al. Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer 2008, 113(4):826-833.
98. Temel J.S., Greer J.A., Muzikansky A., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. NEJM 2010, 363(8):733-742.
99. Temel J.S., Greer J.A., Admane S., Gallagher E., Jackson V.A., et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer. J. Oncol. 2011, 29(17):2319-2326.
100. Timmermans S., Haas S. Towards a sociology of disease. Sociol. Health Illn. 2008, 30(5):659-676.
101. Trowbridge R.L., Walker S. The FDA's deadly track record. Wall Str. J. August 14, 2007, Available at:, (accessed 14.11.13.). http://abigail-alliance.org/WSJ%20OP-ED%20FDA%27s_Deadly_Track_Rec%2008-14-07.pdf.
102. UK Patient Advocate A Interview with UK cancer Patient Advocate 7 July 2011.
103. UK Patient Advocate B Interview with UK cancer Patient Advocate 20 July 2011.
104. UK Patient Advocate C Interview with UK cancer Patient Advocate 23 August 2012.
105. Unger J., Barlow W., Martin D.P., Ramsey S., LeBlanc M., Hershman D.L. Comparison of survival outcomes of patients treated in and out of clinical trials. J. Natl. Cancer Inst. 2014, First published online: March 13, 2014. 10.1093/jnci/dju002.
106. US Patient Advocate A Inteview with US cancer Patient Advocate 24 September 2009.
107. US Patient Advocate B Interview with US cancer Patient Advocate 17 August 2010.
108. US Patient Advocate C Interview with US cancer Patient Advocate 7 September 2011.
109. US Patient Advocate D Interview with US cancer Patient Advocate 8 September 2011.
110. US Patient Advocate E Interview with US cancer Patient Advocate 12 September 2011.
111. US Patient Advocate F Interview with US cancer Patient Advocate 14 September 2011.
112. Vera-Badillo F.E., Shapiro R., Ocana A., et al. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann. Oncol. 2013, 24:1238-1244.
113. von Gruenigen V.E., Daly B.J. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol. Oncol. 2005, 97:638-644.
114. von Gruenigen V., Daly B., Gibbons H., Hutchins J., Green A. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer 2008, 112(10):2221-2227.
115. Weeks J.C., Catalano P., Cronin A. Patients' expectations about effects of chemotherapy for advanced cancer. New Engl. J. Med. 2012, 367(17):1616-1625.
116. Wells K., Pettypiece S. Miracle Cancer Drug Extends Life With $48,720 Cost 5 March 2010, Bloomber, Available at:, (Accessed). http://www.bloomberg.com/apps/news?pid=newsarchive%26sid=aER.9zj2HmSk.
117. Wick C., Egger M., Trelle S., Juni P., Fey M.F. The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Ann. Oncol. 2007, 18(9):1580-1582.
118. Williams S.J., Martin P., Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociol. Health Illn. 2011, 33(5):710-725.
119. WHO Background Paper 6.5 on Cancer and Cancer Therapeutics. Priority Medicines for Europe and the World 2013, Update on 2004 background paper. Available at:, (accessed 14.11.13.). http://www.who.int/medicines/areas/priority_medicines/BP6_5cancer.pdf.
120. Wright A.A., Zhang B., Keating N.L., Weeks J.C., Prigerson H.G. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ 2014, Published 4 March 2014. 10.1136/bmj.g1219.
121. Zafar S.Y., Peppercorn J.M., Schrag D., et al. The financial toxicity of cancer treatments: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013, 18:381-390.